DRL receives USFDA approval for extended-release Dipyridamole capsules

Dr Reddy’s Laboratories Ltd has received USFDA approval for Aspirin and extended-release Dipyridamole capsules. The drug is a therapeutic equivalent generic version of Aggrenox (Aspirin and extended-release Dipyridamole) capsules. Aggrenox is a registered trademark of Boehringer Ingelheim. The company is working towards launching the product in the US market.

The brand Aggrenox and generic has US sales of approximately $183 million for the most recent 12 months ended August 2018.

Company Profile : Dr Reddys Laboratories Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.